On Monday, Tango Therapeutics Inc (NASDAQ: TNGX) opened higher 0.19% from the last session, before settling in for the closing price of $5.15. Price fluctuations for TNGX have ranged from $5.07 to $13.01 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 132.62%. Company’s average yearly earnings per share was noted -22.90% at the time writing. With a float of $59.11 million, this company’s outstanding shares have now reached $102.20 million.
Let’s determine the extent of company efficiency that accounts for 140 employees. In terms of profitability, gross margin is 94.15%, operating margin of -311.57%, and the pretax margin is -273.63%.
Tango Therapeutics Inc (TNGX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tango Therapeutics Inc is 44.83%, while institutional ownership is 56.75%. The most recent insider transaction that took place on Oct 25 ’24, was worth 4,348,710. In this transaction of this company sold 633,000 shares at a rate of $6.87, taking the stock ownership to the 6,690,642 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Member of group owning over 10 proposed sale 100,000 for $6.29, making the entire transaction worth $629,000.
Tango Therapeutics Inc (TNGX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.23 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.34) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.90% per share during the next fiscal year.
Tango Therapeutics Inc (NASDAQ: TNGX) Trading Performance Indicators
Check out the current performance indicators for Tango Therapeutics Inc (TNGX). In the past quarter, the stock posted a quick ratio of 7.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.13, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.46 in one year’s time.
Technical Analysis of Tango Therapeutics Inc (TNGX)
Looking closely at Tango Therapeutics Inc (NASDAQ: TNGX), its last 5-days average volume was 1.42 million, which is a jump from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 2.82%. Additionally, its Average True Range was 0.48.
During the past 100 days, Tango Therapeutics Inc’s (TNGX) raw stochastic average was set at 1.30%, which indicates a significant decrease from 3.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.71% in the past 14 days, which was lower than the 75.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.04, while its 200-day Moving Average is $8.91. However, in the short run, Tango Therapeutics Inc’s stock first resistance to watch stands at $5.28. Second resistance stands at $5.40. The third major resistance level sits at $5.50. If the price goes on to break the first support level at $5.05, it is likely to go to the next support level at $4.95. Now, if the price goes above the second support level, the third support stands at $4.83.
Tango Therapeutics Inc (NASDAQ: TNGX) Key Stats
There are currently 107,144K shares outstanding in the company with a market cap of 523.87 million. Presently, the company’s annual sales total 36,530 K according to its annual income of -101,740 K. Last quarter, the company’s sales amounted to 19,880 K and its income totaled -25,550 K.
